Lincoln Pharmaceuticals Ltd - 531633 - Statement Of Investor Complaints For The Quarter Ended June 2019
No.of Investor complaints pending at the beginning of the quarter No.of Investor complaints received during the quarter No.of Investor complaints disposed of during the quarter No.of Investor complaints unresolved at the end of the quarter 0000 Name of the Signatory :- MAHENDRA GULABDAS PATELDesignation :- Director Lincoln Pharmaceuticals Ltd - 531633 - Disclosure Of Related Party Transactions For The Half Year Ended March 31, 2019, Pursuant To Regulation 23(9) Of SEBI (LODR) Regulations 2015
Pursuant to Regulation 23(9) of SEBI (Listing Obligations and Disclosure Requirements) Regulations, 2015, please find enclosed details of Related Party Transactions for the Half Year Ended March 31, 2019 on consolidated basis. Lincoln Pharmaceuticals Ltd - 531633 - Closure of Trading Window
Pursuant to SEBI [Prohibition of Insider Trading] Regulations, 2015 read with SEBI [Prohibition of Insider Trading] [Amendment] Regulations, 2018 and Code of Practices & Procedures for Fair Disclosure of Unpublished Price Sensitive Information adopted by the Company it is informed that the Trading Window for dealing in securities of the Company shall remain closed from July 01, 2019 till 48 hours after the declaration of Financial Results of the Company for the Quarter Ended on June 30, 2019. LINCOLN PHARMACEUTICALS LTD. - 531633 - Corporate Action-Board approves Dividend
The Board of Directors of the Company at their meeting held today, i.e. on May 30, 2019 had considered following: Recommended the Dividend of Rs. 1.50 (@ 15%) Per Share of Face Value of Rs. 10/- Each of the Company, subject to the approval of Shareholders at the Ensuring Annual General Meeting. LINCOLN PHARMACEUTICALS LTD. - 531633 - Board recommends Dividend
Lincoln Pharmaceuticals Ltd has informed BSE that the Board of Directors of the Company at its Meeting held on May 30, 2019, inter alia, has recommended the Dividend of Rs. 1.50 (@ 15%) Per Share of Face Value of Rs. 10/- Each of the Company, subject to the approval of Shareholders at the Ensuring Annual General Meeting. Lincoln Pharmaceuticals Ltd - 531633 - Result-Financial Result For The Quarter And Year Ended March 31, 2019
The Board of Directors of the Company at their meeting held today, i.e. on May 30, 2019 had considered following: 1.Approved the Audited Standalone and Consolidated Financial Results along with Statement of Assets and Liabilities of the Company for the Quarter and Year Ended on March 31, 2019. 2.Auditors' Report on Audited Standalone and Consolidated Financial Results for the Quarter and Year Ended on March 31, 2019 as received from M/s. J. T. Shah & Co., Statutory Auditors of the Company. 3.Recommended the Dividend of Rs. 1.50 (@ 15%) Per Share of Face Value of Rs. 10/- Each of the Company, subject to the approval of Shareholders at the Ensuring Annual General Meeting. 4.Declaration regarding Un-Modified Opinion on Audited Financial Results by the Statutory Auditors of the Company. 5.The Financial Performance Highlights for the Quarter and Year Ended on March 31, 2019. LINCOLN PHARMACEUTICALS LTD. - 531633 - Reg.24(A)-Annual Secretarial Compliance
Annual Secretarial Compliance Report Sr. No. Particulars Details 1Period for which the report has been issued 31/03/2019 2Date of Report29/05/2019 3 Name of the Certifying Firm Vishwas Sharma & Associates 4 Name of the Certifying Individual Vishwas Sharma 5Membership TypeACS 6 Membership Number 33017 7 CP No. 16942 8 Whether any observations/qualification reported by the Secretarial Auditor ? NO Lincoln Pharmaceuticals Ltd - 531633 - Board Meeting Intimation for Consider And Approve The Audited Standalone And Consolidated Financial Results Of The Company For The Quarter And Year Ended On March 31, 2019 And Recommendation Of Dividend On Equity Shares If Any
LINCOLN PHARMACEUTICALS LTD.has informed BSE that the meeting of the Board of Directors of the Company is scheduled on 30/05/2019 ,inter alia, to consider and approve Consider and approve the Audited Standalone and Consolidated Financial Results of the Company for the Quarter and Year Ended on March 31, 2019, Recommendation of Dividend on Equity Shares of the Company for the Financial Year Ended on March 31, 2019, if any and Any other matter with the approval of the chair. LINCOLN PHARMACEUTICALS LTD. - 531633 - Compliances-Certificate under Reg. 54 (5) of SEBI (DP) Regulations, 1996
confirmation certificate received from Link intime india private limited, Registrar and Share Transfer Agent (RTA) as per regulation 74(5) of the SEBI (Depositories and Participants) Regulations. 2018 for the quarter ended 31st March. 2019